Expression of nkg2d and its ligand in heart allografts may provide a link between innate and adaptive immunity in acute rejection
Li Feng,Zheng Zi Ye,Fu Sheng Li,Qiang Tang,Na Zhao,Ping You Li
2006-01-01
Abstract:Abstract# 2081 Poster Board #-Session: P408-II 2081 Poster Board #-Session: P408-II EXPRESSION OF NKG2D AND ITS LIGAND IN HEART ALLOGRAFTS MAY PROVIDE A LINK BETWEEN INNATE AND ADAPTIVE IMMUNITY IN ACUTE REJECTION. Li Feng, Zheng Zi Ye, Fu Sheng Li, Qiang Tang, Na Zhao, Ping You Li. Lab of Transplant Engineering and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China. NKG2D is an activating natural cytotoxicity receptor of NK, CD8+αβT and γδT cells. Ligands for NKG2D, such as Rae-1, H60 (mouse) and MIC (human), may be expressed by tissues in response to stress. Recent reports have shown that MIC was expressed in epithelial cells in renal and pancreatic allografts that show histologic evidence of rejection. Since NKG2D-ligand engagement may induce NK cell activation and provide T-cell co-stimulation, we wondered if this interaction between innate and adaptive immunity may occur during heart transplant rejection. Methods. Hearts from BALB/c mice were heterotopically transplanted into C57BL/6 mice without immunosupression (n = 18). Grafts were harvested on 1, 3 and 5 days post-transplantation. Rae-1, H60 and NKG2D mRNA were analyzed by RT-PCR and the proteins were detected by immunohistochemistry (IHC). Results. Compared with no expression in naïve BALB/c mice heart, Rae1 mRNA level in heart allograft was found from 3rd to 5th day postoperation, H60 on 5th day and NKG2D on 3rd day and prominently on 5th day postoperation. Immunohistochemical assay found that compared with no expression in naïve BALB/c mice heart, protein expression of Rae-1 and NKG2D was found from 3rd to 5th day postoperation and H60 on 5th day postoperation. Furthermore, IHC staining demonstrated infiltration of heart cells by NKG2D+ cells progressively increased with rejection. Conclusion. This study first report the significant mRNA and protein expression of Rae-1, H60 and NKG2D during cardiac allograft acute rejection. The expression of NKG2D ligand and the NKG2D+ cells infiltration progressively increased with rejection. The simultaneous and significant expression of NKG2D and its ligands indicate that an interaction between innate (NKG2D-Rae-1 and NKG2D-H60 co-stimulation) and cognate (donor NKG2D+ immunocytes) immunity may promote acute rejection in heart transplantation. These results also suggested Rae-1 and H60 might become the new interfering targets for prevention. Since innate immunity provides early obstacles to successful organ transplantation and NK cells are not well targeted by current immunosuppression, control of innate immunity and NK cell activity may offer a valuable new possibility for improving the short and long-term outcome of transplanted organs. Abstract# 2082 Poster Board #-Session: P409-II 2082 Poster Board #-Session: P409-II RDP1258 ALONE PROLONGS HEART ALLOGRAFT SURVIVAL IN RAT VIA ANTI-INFLAMMATORY AND ANTI-APOPTOTIC EFFECTS. Gang Ye, Gang Zhi Cui, Hou Zhe Wang, Hong Shan Yi, Wei Xiang Wang, Qiang Zhen Fang. Department of Urology, Center of Nephrology, Xin Qiao Hospital, Third Military Medical University, Chongqing, China. Modification of the HLA-derived peptide’s sequence in combination with computer-aided rational design resulted in a peptide, RDP1258. Use of RDP1258 plus cyclosporine (CsA) has shown to prolong allograft survival in rodents. This study aimed to analyze the effect of RDP1258 alone on heart transplant and the possible mechanism by which it enhances immunosuppressive activity. Cardiac allografts from SD rats were transplanted into the infrarenal abdominal aorta of Wistar rats. The animal groups received different regimens of treatment with RDP1258 alone, CsA alone, RDP1258+ CsA, and saline respectively. RDP1258 was administrated intraperitoneally at a dose of 5mg/kg per day on days -7,-1 and 0 until day 5 posttransplant. CsA in all cases was gavaged at a dose of 5mg/kg per day from days 0 to 5. Graft survival was monitored daily by direct palpation through the abdominal wall and rejection was defined as cessation of cardiac beating. In additions we evaluated the activity of this peptide, analyzing the severity of acute rejection by pathologic exam, intragraft TNFα and INFγ transcripts by RT-PCR, and intragraft apoptosis of the grafted heart harvested at the day 7 posttransplant. RDP1258 alone resulted in a significant prolongation of graft survival compared either with control group or CsA group (33.29±10.09 vs. 8.0±2.9 and 13.38±3.62 days, P<0.05), although a combination of RDP1258/CsA produced the maximum prolongation of graft survival (85.38±18.34 days, p<0.05). This effect was consistent with an attenuated severity of acute rejection and associated with a decreased intragraft TNFαmRNA transcript and cell apoptosis. The ratio of TNFα : β-actin values in heart grafts from RDP1258-treated rats was about a half times as the same as that both in control and CsA groups. Staining for TUNEL demonstrated intragraft cell apoptosis index was significantly lower in RDP1258 group than CsA group, with the highest one in control group. There is no significant difference of intragraft TNFα transcript or cell apoptosis index between RDP1258 and CsA /RDP1258 groups. Intragraft IFNγ mRAN expression did not differ significantly among all 4 groups. In conclusion, RDP1258 can attenuate heart acute rejection and prolong graft survival. The mechanisms by which RDP1258 suppress graft rejection may involve its ability to suppress cell apoptosis and inflammatory response in the grafted heart. Abstract# 2083 Poster Board #-Session: P410-II 2083 Poster Board #-Session: P410-II SIGNIFICANCE OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ IN ALLOIMMUNE RESPONSE IN VIVO. Masayuki Sho, Takeo Nomi, Takahiro Akahori, Yukiyasu Kuzumoto, Hiromichi Kanehiro, Michiyoshi Hisanaga, Saiho Ko, Yoshiyuki Nakajima. Department of Surgery, Nara Medical University, Kashihara, Nara, Japan. Aims: Peroxisome proliferator-activated receptor γ (PPARγ) is a transcriptional factor belonging to the nuclear receptor superfamily. Accumulating evidence indicates that PPAR mediates a variety of both innate and adaptive immune response through its anti-inflammatory effect. Recent studies have also suggested that PPARγ provokes apoptosis in activated T cells that may be a key mechanism in allograft acceptance. To date, however, the roles of PPARγ in alloimmune response are largely unknown. In this study, we tried to clarify the significance of PPAR in vivo. Methods: To this end, we employed a specific PPAR agonist, pioglitazone in a fully MHC-mismatched vascularized murine cardiac allograft model (C57BL/6 into BALB/c). We have also performed histological analysis, ELISPOT and real-time PCR to address mechanisms. Results: We first examined the expression of PPARγ in untreated cardiac allografts. As a result, PPARγ expression in rejecting grafts was upregulated in the process of acute rejection suggesting that PPARγ may play some roles in alloimmune response. Then we treated mice with pioglitazone (20mg/kg, daily, d0-14). Interestingly, PPARγ agonist treatment significantly prevented acute allograft rejection and prolonged cardiac allograft survival (P=0.0002, n=6, MST=16d, vs. controls, MST=7d). Histological analysis also confirmed the protective effect of PPARγ agonist. These findings are suggestive that PPARγ is functionally important and plays critical roles in alloimmune response. To address the underlying mechanisms, we evaluated T cell response and local immune status in transplanted allografts. ELISPOT analysis has shown that PPARγ agonist significantly inhibited alloreactive T cell response. Furthermore, the treatment significantly downregulated the intragraft expressions of cytokine (TNF-α and IFN-γ; P<0.0001 and P=0.03, respectively, compared to controls), chemokine (RANTES; P=0.01) and adhesion molecule (E-selectin, P=0.01), as determined by real-time PCR analysis. Thus, the beneficial effect of PPARγ agonist on allograft rejection was associated with the inhibition of T cell activation as well as local immune activation. Conclusions: Our data demonstrates for the first time that PPARγ may be a critical regulator in alloimmune response in vivo. Specific agonist for PPARγ may represent a novel therapy for the protection of allograft rejection in clinical transplantation.